Condition: Acute Lymphocytic Leukemia Refractory · Lymphoma, Lymphoblastic · Sponsor: Imviva Bio
The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients. Participants with relapsed/refractory T-ALL/LBL over the age of 12 will be eligible to participate. Participants will receive one infusion of CTD402 on Day 0 and will be evaluated for anti-tumor activity by an independent review committee based on the NCCN criteria for T-ALL and the Lugano 2014 criteria for T-LBL. Patients will be followed for up to 24 months in this study and will be required to enroll under a separate long term follow up protocol to be followed for up to 15 years.
This description comes directly from the study's public registry record.
Jan Davidson-Moncada, MD, PhD · 917-573-8538 · clinicaltrials@bioheng.com
Always discuss trial participation with your own doctor first.
| Stanford University | Palo Alto, California, United States | Recruiting |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Not Yet Recruiting |
| University of Chicago | Chicago, Illinois, United States | Not Yet Recruiting |
| Mayo Clinic - Rochester | Rochester, Minnesota, United States | Not Yet Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Montefiore Einstein Comprehensive Cancer Center | The Bronx, New York, United States | Recruiting |
| Sarah Cannon Research Insitute | Nashville, Tennessee, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07070219